checkAd

     129  0 Kommentare Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

    • TD Cowen 44th Annual Health Care Conference
      Date: Wednesday, March 6, 2024
      Presentation Time: 12:50 p.m. ET / 9:50 a.m. PT
      Location: Boston

    • Leerink Partners Global Biopharma Conference
      Date: Tuesday, March 12, 2024
      Presentation Date/Time: Wednesday, March 13, 2024, 9:20 a.m. ET / 6:20 a.m. PT
      Location: Miami

    • Jefferies Biotech on the Bay Summit
      Date: Wednesday, March 13, 2024
      Location: Miami

    • Barclays Global Healthcare Conference
      Date: Thursday, March 14, 2024
      Presentation Time: 11:15 a.m. ET / 8:15 a.m. PT
      Location: Miami

    Live webcasts of the Cowen, Leerink and Barclays presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

    About Xencor

    Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.


    The Xencor Stock at the time of publication of the news with a fall of -13,80 % to 22,86USD on Nasdaq stock exchange (28. Februar 2024, 21:50 Uhr).



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Xencor to Present at Upcoming Investor Conferences Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor …